---
title: PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in
  patients with progressive glioblastoma
date: '2024-01-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38279087/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240127170650&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: Glioblastoma is the most frequent and a particularly malignant
  primary brain tumor with no efficacy-proven standard therapy for recurrence. It
  has recently been discovered that excitatory synapses of the AMPA-receptor subtype
  form between non-malignant brain neurons and tumor cells. This neuron-tumor network
  connectivity contributed to glioma progression and could be efficiently targeted
  with the EMA/FDA approved antiepileptic AMPA receptor inhibitor perampanel in ...'
disable_comments: true
---
BACKGROUND: Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain neurons and tumor cells. This neuron-tumor network connectivity contributed to glioma progression and could be efficiently targeted with the EMA/FDA approved antiepileptic AMPA receptor inhibitor perampanel in ...